JP2023525100A5 - - Google Patents
Info
- Publication number
- JP2023525100A5 JP2023525100A5 JP2022568601A JP2022568601A JP2023525100A5 JP 2023525100 A5 JP2023525100 A5 JP 2023525100A5 JP 2022568601 A JP2022568601 A JP 2022568601A JP 2022568601 A JP2022568601 A JP 2022568601A JP 2023525100 A5 JP2023525100 A5 JP 2023525100A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- pharmaceutically acceptable
- use according
- compound
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023470P | 2020-05-12 | 2020-05-12 | |
| US63/023,470 | 2020-05-12 | ||
| PCT/IB2021/054013 WO2021229439A1 (en) | 2020-05-12 | 2021-05-11 | Therapeutic combinations comprising a craf inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023525100A JP2023525100A (ja) | 2023-06-14 |
| JP2023525100A5 true JP2023525100A5 (https=) | 2024-05-21 |
Family
ID=75954158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568601A Pending JP2023525100A (ja) | 2020-05-12 | 2021-05-11 | Ｃｒａｆ阻害剤を含む治療的組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240000789A1 (https=) |
| EP (1) | EP4149472A1 (https=) |
| JP (1) | JP2023525100A (https=) |
| CN (1) | CN115551509A (https=) |
| TW (1) | TW202207942A (https=) |
| WO (1) | WO2021229439A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| WO2024148307A1 (en) * | 2023-01-06 | 2024-07-11 | Erasca, Inc. | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1761528T1 (sl) | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
| GB0719771D0 (en) * | 2007-10-10 | 2007-11-21 | Therapeutics Ltd E | Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| KR20190057421A (ko) * | 2012-08-17 | 2019-05-28 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| CN111053768B (zh) * | 2013-07-12 | 2023-12-12 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
| AP2016009099A0 (en) | 2013-11-01 | 2016-03-31 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
| PL3319993T3 (pl) * | 2015-07-10 | 2020-07-27 | Genmab A/S | Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka |
| EP3340987A1 (en) * | 2015-08-28 | 2018-07-04 | Novartis AG | Combination of ribociclib and dabrafenib for treating or preventing cancer |
| AU2017329090B9 (en) * | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| CA3057969A1 (en) * | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| TW202023556A (zh) * | 2018-08-27 | 2020-07-01 | 美商庫拉腫瘤技術股份有限公司 | 以mapk路徑抑制劑治療腺癌 |
| CA3123510A1 (en) * | 2018-12-20 | 2020-06-25 | Novartis Ag | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer |
| EP4106756A1 (en) * | 2020-02-18 | 2022-12-28 | Novartis AG | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc |
-
2021
- 2021-05-11 US US17/998,391 patent/US20240000789A1/en active Pending
- 2021-05-11 EP EP21726201.3A patent/EP4149472A1/en active Pending
- 2021-05-11 WO PCT/IB2021/054013 patent/WO2021229439A1/en not_active Ceased
- 2021-05-11 CN CN202180034241.6A patent/CN115551509A/zh active Pending
- 2021-05-11 JP JP2022568601A patent/JP2023525100A/ja active Pending
- 2021-05-12 TW TW110117160A patent/TW202207942A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023525100A5 (https=) | ||
| Gogas et al. | Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management | |
| JP2024133475A5 (https=) | ||
| JP2024133474A5 (https=) | ||
| JP2018519340A5 (https=) | ||
| JP2022544234A (ja) | 胃腸間質腫瘍を治療するためのリプレチニブ | |
| JP2014518880A (ja) | ピルフェニドン及び選択された患者における抗線維化療法 | |
| JP2019517587A5 (https=) | ||
| JP2024516795A (ja) | エベロリムスおよびアムセネストラントを含む組合せ物 | |
| EP2802352A1 (en) | Combination therapy for the treatment of cancer | |
| US20240398809A1 (en) | Treatment of alopecia areata | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| EP4580631A1 (en) | Dosage regimens of estrogen receptor degraders | |
| CN104039148A (zh) | 组合als疗法 | |
| EP4106756A1 (en) | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc | |
| JP2020516663A5 (https=) | ||
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP6437444B2 (ja) | 医薬的組合せ | |
| US8765720B2 (en) | Combination therapy for the treatment of multiple myeloma | |
| JP2005513167A5 (https=) | ||
| JP2006508118A5 (https=) | ||
| CN111163781B (zh) | 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合 | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| US11179395B2 (en) | Treating melanoma with mebendazole and a mitogen-activated kinase inhibitor | |
| WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders |